Net profit of Marksans Pharma rose 8.26% to Rs 113.20 crore in the quarter ended December 2025 as against Rs 104.56 crore during the previous quarter ended December 2024. Sales rose 10.64% to Rs 754.43 crore in the quarter ended December 2025 as against Rs 681.85 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales754.43681.85 11 OPM %21.3120.35 - PBDT174.95163.95 7 PBT150.62143.26 5 NP113.20104.56 8 Powered by Capital Market - Live News

Marksans Pharma has formed and incorporated the following two new wholly owned subsidiary companies: 1. Marksans Pharma (Europe) in Ireland 2. Marksans (Canada) Inc. in Canada Powered by Capital Market - Live News

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live News

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution from UK MHRA. Powered by Capital Market - Live News

Marksans Pharma announced USFDA final approval of the Company`s wholly owned subsidiary Marksans Pharma Inc.`s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860. Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.Powered by Capital Market - Live News